Given the FDA’s decision to initiate the removal of boxed warning labels from hormone therapy products, it may be prescribed ...
CK0804, a regulatory T cell therapy, received FDA orphan drug designation for myelofibrosis, supporting rare disease treatment development. Clinical study results showed significant reductions in ...
Tividenofusp alfa treatment showed reduction and normalization in key disease biomarkers, stabilization or improvement in clinical endpoints including adaptive behavior, cognition and hearing, and ...
As 2026 begins, a slate of high-stakes clinical readouts—from a pivotal study of Novartis’ cardiovascular candidate ...
Early Data Suggests a Trend Toward Improvement in Pain Efficacy SASKATOON, SK, Jan. 8, 2026 /CNW/ – ZYUS Life Sciences ...
Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations KB407 transduction confirmed in all six patients with successful bronchoscopies irrespect ...
New research finds statins benefit adults with type 2 diabetes across all heart-risk levels, reducing deaths and serious ...
Menon serves on the Lancet Commission on “Strengthening the use of Epidemiological Modelling of Pandemic Diseases”, and heads ...
Preparing for FDA approval and commercial launch of tividenofusp alfa, Denali’s TransportVehicle™ (TV)-enabled investigational therapy for Hunter ...
KELOWNA, BC / / December 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback